When Cheri Ferguson started taking Ozempic last year, she said, she hoped to lose about 50 pounds she’d gained during the Covid-19 pandemic. Over about three months, she told CNN in June, the medicine – which is approved for type 2 diabetes and used off-label for weight loss – helped reduce the constant chatter in her brain urging her to eat,

Novo Nordisk's trailing-12-month net income rose by 82% over the last three years, reaching nearly $13 billion. Its GLP-1 drugs, including Ozempic and Wegovy, grew by 30% as a segment year-over-year in the first quarter, driving the company's overall growth.

Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the cost of the effective but expensive drug.

Novo Nordisk is trialling its weight-loss drugs to explore if they can reduce alcohol intake and treat alcoholic liver disease, as it seeks to expand the uses of the blockbuster treatments. The Danish pharmaceutical company has started recruitment for a mid-stage trial looking at whether an estimated 240 patients using semaglutide,

Novo Nordisk (NVO) plans to run a Phase 2 study to determine whether their weight loss drugs can impact alcohol use in patients with liver disease. Read more here.